02175nas a2200301   4500008004100000022001400041245010200055210006900157260009200226300001400318490000700332520111600339653001501455653002301470653002201493653001901515653001701534653002201551100002301573700002901596700001901625700001801644700002101662700002401683700001901707700002101726856012601747       2015                        eng d  a1478-641900aNew butenolide cinnamate and other biological active chemical constituents from Polygonum glabrum0 aNew butenolide cinnamate and other biological active chemical co  a4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLANDbTAYLOR & FRANCIS LTDcNOV  a2080-20860 v293 a<p>Phytochemical investigation of the methanol extract of the aerial parts of Polygonum glabrum afforded one new natural product (-)-2-methoxy-2-butenolide-3-cinnamate (1) along with six known compounds, -hydroxyfriedalanol (2), 3-hydroxy-5-methoxystilbene (3), (-) pinocembrin (4), sitosterol-(6-O-palmitoyl)-3-O–d-glucopyranoside (5), (-) pinocembrin-5-methyl ether (6) and sitosterol-3-O–d-glucopyranoside (7). Compound 1 showed promising in vitro anti-HIV-1 activity against primary isolates HIV-1(UG070) (X4, subtype D) and HIV-1(VB59) (R5, subtype C) assayed using TZM-bl cell line with IC50 in the range of 15.68-22.43g/mL. The extract showed TI in the range of 19.19-27.37 with IC50 in the range of 10.90-15.55g/mL. Compounds 1, 3 and 4 exhibited in vitro anti-mycobacterium activity against Mycobacterium tuberculosis H37Ra with IC50 values of 1.43, 3.33 and 1.11g/mL in dormant phase and 2.27, 3.33 and 1.21g/mL in active phase, respectively. Compound 4 was found to be the most active antiproliferative with IC50 values of 1.88-11.00g/mL against THP-1, A549, Panc-1, HeLa and MCF7 cell lines.</p>10aanti-HIV-110aanti-mycobacterium10aantiproliferative10aphytochemicals10aPolygonaceae10aPolygonum glabrum1 aSaid, Madhukar, S.1 aChinchansure, Ashish, A.1 aNawale, Laxman1 aDurge, Ankita1 aWadhwani, Ashish1 aKulkarni, Smita, S.1 aSarkar, Dhiman1 aJoshi, Swati, P.  uhttps://library.ncl.res.in/content/new-butenolide-cinnamate-and-other-biological-active-chemical-constituents-polygonum-000818nas a2200241   4500008004100000022001400041245010700055210006900162260000900231300000800240490000700248653001500255653001300270653002100283653001900304653001600323100002400339700002500363700002200388700002400410700001600434856012600450       2020                        eng d  a1663-981200aPhytochemicals in cancer treatment: from preclinical studies to clinical practice (vol 10, 1614, 2020)0 aPhytochemicals in cancer treatment from preclinical studies to c  cFEB   a1750 v1110aAnticancer10aclinical10amedicinal plants10aphytochemicals10apreclinical1 aChoudhari, Amit, S.1 aMandave, Pallavi, C.1 aDeshpande, Manasi1 aRanjekar, Prabhakar1 aPrakash, Om  uhttps://library.ncl.res.in/content/phytochemicals-cancer-treatment-preclinical-studies-clinical-practice-vol-10-1614-202002459nas a2200253   4500008004100000022001400041245008600055210006900141260000800210300000900218490000700227520166700234653001501901653001301916653002101929653001901950653001601969100002401985700002502009700002202034700002402056700001602080856010902096       2020                        eng d  a1663-981200aPhytochemicals in cancer treatment: from preclinical studies to clinical practice0 aPhytochemicals in cancer treatment from preclinical studies to c  cJAN  a16140 v103 a<p>Cancer is a severe health problem that continues to be a leading cause of death worldwide. Increasing knowledge of the molecular mechanisms underlying cancer progression has led to the development of a vast number of anticancer drugs. However, the use of chemically synthesized drugs has not significantly improved the overall survival rate over the past few decades. As a result, new strategies and novel chemoprevention agents are needed to complement current cancer therapies to improve efficiency. Naturally occurring compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer therapy. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, and podophyllotoxin analogs. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system. The primary objective of this review is to describe what we know to date of the active compounds in the natural products, along with their pharmacologic action and molecular or specific targets. Recent trends and gaps in phytochemical based anticancer drug discovery are also explored. The authors wish to expand the phytochemical research area not only for their scientific soundness but also for their potential druggability. Hence, the emphasis is given to information about anticancer phytochemicals which are evaluated at preclinical and clinical level.</p>
10aAnticancer10aclinical10amedicinal plants10aphytochemicals10apreclinical1 aChoudhari, Amit, S.1 aMandave, Pallavi, C.1 aDeshpande, Manasi1 aRanjekar, Prabhakar1 aPrakash, Om  uhttps://library.ncl.res.in/content/phytochemicals-cancer-treatment-preclinical-studies-clinical-practice02485nas a2200253   4500008004100000022001400041245020000055210006900255260000900324300001400333490000700347520152300354653002601877653001301903653002201916653003401938653001901972100002101991700002002012700002602032700002702058700002302085856012302108       2024                        eng d  a0739-110200aRepurposing phytochemicals of Citrullus colocynthis against maltase-glucoamylase using molecular docking, MMGBSA, MD simulation and linear regression to identify potential anti-diabetic compounds0 aRepurposing phytochemicals of Citrullus colocynthis against malt  cJUL   a5197-52060 v423 a<p>
	Diabetes is a common lifestyle disorder found in populations of different age groups. Maltase-glucoamylase catalyses the release of the glucose molecule in the final enzymatic reaction of starch digestion; therefore, inhibition of maltase-glucoamylase is one of the approaches in the development of therapeutics for diabetes. Citrullus colocynthis is commonly recommended in Ayurveda for the treatment of diabetes. The current study applied a structure-based drug design approach to repurpose the phytochemicals of Citrullus colocynthis to identify potential inhibitors for maltase-glucoamylase. 70 phytochemicals of Citrullus colocynthis were screened against maltase-glucoamylase and top 5 molecules 8-p-hydroxybenzylisovitexin, isoorientin, cucurbitacin B, cucurbitacin E, and cucurbitacin I with significant binding energy of -10 kcal/mol, -9.9 kcal/mol, -9.6 kcal/mol, -9.2 kcal/mol, and -7.7 kcal/mol were identified. Furthermore, MMGBSA, pharmacokinetics properties and toxicity prediction were performed on the five identified molecules and top 3 molecules were selected for molecular dynamics (MD) simulation. It was observed from the structural flexibility and dynamic behaviour of the systems that conformational changes were noticed in the complexes as compared to its native state, which suggests that the 3 molecules, namely 8-p-hydroxybenzylisovitexin, isoorientin, and cucurbitacin I of Citrullus colocynthis may act as inhibitors for maltase-glucoamylase.Communicated by Ramaswamy H. Sarma</p>
10aCitrullus colocynthis10aDiabetes10alinear regression10amolecular dynamics simulation10aphytochemicals1 aSahu, Parameswar1 aSahoo, Rosaleen1 aSahu, Abhishek, Kumar1 aSaluja, Sundeep, Singh1 aBehera, Banshidhar  uhttps://library.ncl.res.in/content/repurposing-phytochemicals-citrullus-colocynthis-against-maltase-glucoamylase-using